151602-49-2 Usage
Description
5-O-DESMETHYL OMEPRAZOLE is a metabolite of Omeprazole, which is an antiulcerative agent. It is a light-yellow solid with chemical properties that make it a valuable compound in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
5-O-DESMETHYL OMEPRAZOLE is used as an active pharmaceutical ingredient (API) for the development of antiulcerative medications. As a metabolite of Omeprazole, it contributes to the therapeutic effects of the parent drug, helping in the treatment and management of ulcers and related gastrointestinal disorders.
Used in Research and Development:
5-O-DESMETHYL OMEPRAZOLE is used as a research compound for studying the pharmacological properties and mechanisms of action of Omeprazole and its derivatives. This helps in understanding the drug's efficacy, safety, and potential for further development in the treatment of various gastrointestinal conditions.
Used in Quality Control and Standardization:
5-O-DESMETHYL OMEPRAZOLE is used as a reference standard in the quality control and standardization of pharmaceutical products containing Omeprazole. It ensures the accuracy and reliability of analytical methods and helps in maintaining the quality and consistency of the final product.
Used in Drug Metabolism Studies:
5-O-DESMETHYL OMEPRAZOLE is used as a model compound in drug metabolism studies, providing insights into the metabolic pathways and biotransformation processes of Omeprazole in the body. This information is crucial for optimizing drug dosages, understanding drug interactions, and predicting potential side effects.
Used in Drug Synthesis:
5-O-DESMETHYL OMEPRAZOLE can be used as a starting material or intermediate in the synthesis of novel antiulcerative drugs or other related pharmaceutical compounds. Its unique chemical properties make it a valuable building block for the development of new therapeutic agents with improved efficacy and safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 151602-49-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,1,6,0 and 2 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 151602-49:
(8*1)+(7*5)+(6*1)+(5*6)+(4*0)+(3*2)+(2*4)+(1*9)=102
102 % 10 = 2
So 151602-49-2 is a valid CAS Registry Number.
151602-49-2Relevant articles and documents
Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes
Yamazaki,Shimada
, p. 231 - 241 (1999)
1. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by 12 recombinant human cytochrome P450 (P450 or CYP) enzymes and by human liver microsomes have been investigated. 2. Arachidonic acid (50 μM) significantly inhibited CYP1A1- and 1A2-dependent 7-ethoxycoumarin O-deethylations, CYP2C8-dependent taxol 6α-hydroxylation and CYP2C19-dependent R-warfarin 7-hydroxylation. This chemical also inhibited slightly the xenobiotic oxidations catalysed by CYP1B1, 2B6, 2C9, 2D6, 2E1 and 3A4 in recombinant enzyme systems. 3. Retinol, retinoic acid and cholecalciferol were strong inhibitors for xenobiotic oxidations catalysed by recombinant CYP1A1, 2C8 and 2C19. 4. Dixon plots of inhibitions of CYP1A1-, 1A2-, 2C8- and 2C19-dependent xenobiotic oxidations by arachidonic acid, of CYP1A1-, 2B6- and 2C19-dependent activities by retinol, and of CYP1A1- and 2C19-dependent activities by cholecalciferol indicated that these chemicals inhibit P450 activities mainly through a competitive mechanism. 5. In human liver microsomes, arachidonic acid inhibited CYP1A2-dependent theophylline hydroxylation, CYP2C8-dependent taxol 6α-hydroxylation and CYP2C19-dependent omeprazole 5-hydroxylation. Taxol 6α-hydroxylation was also inhibited by retinol and retinoic acid, and omeprazole 5-hydroxylation was inhibited by retinol in human liver microsomes. 6. These results suggest that xenobiotic oxidations by P450 enzymes are affected by endobiotic chemicals and that the endobiotic-xenobiotic interactions as well as drug-drug interactions may be of great importance when understanding the basis for pharmacological and toxicological actions of a number of xenobiotic chemicals.
